IBDEI0OI ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11012,2)
 ;;=^5003413
 ;;^UTILITY(U,$J,358.3,11013,0)
 ;;=F18.188^^42^498^12
 ;;^UTILITY(U,$J,358.3,11013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11013,1,3,0)
 ;;=3^Inhalant Induced Mild Neurocog Disorder w/ Mild Use Disorder
 ;;^UTILITY(U,$J,358.3,11013,1,4,0)
 ;;=4^F18.188
 ;;^UTILITY(U,$J,358.3,11013,2)
 ;;=^5003390
 ;;^UTILITY(U,$J,358.3,11014,0)
 ;;=F18.288^^42^498^13
 ;;^UTILITY(U,$J,358.3,11014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11014,1,3,0)
 ;;=3^Inhalant Induced Mild Neurocog Disorder w/ Mod/Severe Use Disorder
 ;;^UTILITY(U,$J,358.3,11014,1,4,0)
 ;;=4^F18.288
 ;;^UTILITY(U,$J,358.3,11014,2)
 ;;=^5003403
 ;;^UTILITY(U,$J,358.3,11015,0)
 ;;=F18.988^^42^498^14
 ;;^UTILITY(U,$J,358.3,11015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11015,1,3,0)
 ;;=3^Inhalant Induced Mild Neurocog Disorder w/o Use Disorder
 ;;^UTILITY(U,$J,358.3,11015,1,4,0)
 ;;=4^F18.988
 ;;^UTILITY(U,$J,358.3,11015,2)
 ;;=^5003415
 ;;^UTILITY(U,$J,358.3,11016,0)
 ;;=F18.159^^42^498^15
 ;;^UTILITY(U,$J,358.3,11016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11016,1,3,0)
 ;;=3^Inhalant Induced Psychotic Disorder w/ Mild Use Disorder
 ;;^UTILITY(U,$J,358.3,11016,1,4,0)
 ;;=4^F18.159
 ;;^UTILITY(U,$J,358.3,11016,2)
 ;;=^5003387
 ;;^UTILITY(U,$J,358.3,11017,0)
 ;;=F18.259^^42^498^16
 ;;^UTILITY(U,$J,358.3,11017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11017,1,3,0)
 ;;=3^Inhalant Induced Psychotic Disorder w/ Mod/Severe Use Disorder
 ;;^UTILITY(U,$J,358.3,11017,1,4,0)
 ;;=4^F18.259
 ;;^UTILITY(U,$J,358.3,11017,2)
 ;;=^5003400
 ;;^UTILITY(U,$J,358.3,11018,0)
 ;;=F18.959^^42^498^17
 ;;^UTILITY(U,$J,358.3,11018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11018,1,3,0)
 ;;=3^Inhalant Induced Psychotic Disorder w/o Use Disorder
 ;;^UTILITY(U,$J,358.3,11018,1,4,0)
 ;;=4^F18.959
 ;;^UTILITY(U,$J,358.3,11018,2)
 ;;=^5003412
 ;;^UTILITY(U,$J,358.3,11019,0)
 ;;=F18.99^^42^498^24
 ;;^UTILITY(U,$J,358.3,11019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11019,1,3,0)
 ;;=3^Inhalant Related Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,11019,1,4,0)
 ;;=4^F18.99
 ;;^UTILITY(U,$J,358.3,11019,2)
 ;;=^5133360
 ;;^UTILITY(U,$J,358.3,11020,0)
 ;;=F18.11^^42^498^1
 ;;^UTILITY(U,$J,358.3,11020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11020,1,3,0)
 ;;=3^Inhalant Abuse,In Remission
 ;;^UTILITY(U,$J,358.3,11020,1,4,0)
 ;;=4^F18.11
 ;;^UTILITY(U,$J,358.3,11020,2)
 ;;=^5151305
 ;;^UTILITY(U,$J,358.3,11021,0)
 ;;=Z00.6^^42^499^1
 ;;^UTILITY(U,$J,358.3,11021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11021,1,3,0)
 ;;=3^Exam of Participant of Control in Clinical Research Program
 ;;^UTILITY(U,$J,358.3,11021,1,4,0)
 ;;=4^Z00.6
 ;;^UTILITY(U,$J,358.3,11021,2)
 ;;=^5062608
 ;;^UTILITY(U,$J,358.3,11022,0)
 ;;=F45.22^^42^500^1
 ;;^UTILITY(U,$J,358.3,11022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11022,1,3,0)
 ;;=3^Body Dysmorphic Disorder
 ;;^UTILITY(U,$J,358.3,11022,1,4,0)
 ;;=4^F45.22
 ;;^UTILITY(U,$J,358.3,11022,2)
 ;;=^5003588
 ;;^UTILITY(U,$J,358.3,11023,0)
 ;;=F45.8^^42^500^16
 ;;^UTILITY(U,$J,358.3,11023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11023,1,3,0)
 ;;=3^Somatoform Disorders,Other Specified
 ;;^UTILITY(U,$J,358.3,11023,1,4,0)
 ;;=4^F45.8
 ;;^UTILITY(U,$J,358.3,11023,2)
 ;;=^331915
 ;;^UTILITY(U,$J,358.3,11024,0)
 ;;=F45.0^^42^500^14
 ;;^UTILITY(U,$J,358.3,11024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11024,1,3,0)
 ;;=3^Somatization Disorder
